51
|
Abstract
Sclerosing encapsulating peritonitis (SEP) is a rare complication of chronic peritoneal dialysis and beta-blocker (practolol) usage. The authors report a case of idiopathic SEP developing in a 39-year-old woman with associated ovarian cysts and kerato-conjunctivitis sicca syndrome. These associations have not been reported previously. The histological diagnosis of SEP was made after laparotomy for intestinal obstruction. The patient continues to have chronic intestinal failure, managed conservatively by long-term parenteral nutrition and steroids for more than 12 years.
Collapse
|
52
|
Abstract
Sclerosing encapsulating peritonitis (SEP) is a rare cause of intestinal obstruction that is characterized by a thick grayish-white fibrotic membrane encasing the small bowel. SEP can be classified as idiopathic, also known as abdominal cocoon, or secondary. It is difficult to make a definite pre-operative diagnosis. We experienced five cases of abdominal cocoon, and the case files were reviewed retrospectively for the clinical presentation, operative findings and outcome. All the patients presented with acute, subacute and chronic intestinal obstruction. Computed tomography (CT) showed characteristic findings of small bowel loops congregated to the center of the abdomen encased by a soft-tissue density mantle in four cases. Four cases had an uneventful post-operative period, one case received second adhesiolysis due to persistent ileus. The imaging techniques may facilitate pre-operative diagnosis. Surgery is important in the management of SEP.
Collapse
Affiliation(s)
- Ping Xu
- Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Qingchun Road 79, Hangzhou 310003, Zhejiang Province, China
| | | | | |
Collapse
|
53
|
Moustafellos P, Hadjianastassiou V, Roy D, Velzeboer NE, Maniakyn N, Vaidya A, Friend PJ. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 2007; 38:2913-4. [PMID: 17112862 DOI: 10.1016/j.transproceed.2006.08.179] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2005] [Indexed: 12/11/2022]
Abstract
Sclerosing encapsulating peritonitis (SEP) is a serious complication of long-term continuous ambulatory peritoneal dialysis (CAPD) associated with obstructive symptoms and sclerosis of the peritoneal membrane. We present two cases that were successfully treated with tamoxifen and corticosteroids. Case 1: A 40-year-old patient developed end-stage renal failure (ESRF) and was managed with CAPD. He was hospitalized with symptoms of small bowel obstruction. He underwent laparotomy confirming the diagnosis of SEP. The patient was given tamoxifen 20 mg twice a day. Case 2: A 55-year-old patient with ESRF secondary to membranous glomerulonephritis. After having a cadaveric renal transplant in 1978 that failed 20 years later, the patient returned to CAPD. Six years later he had an uneventful kidney transplant and the peritoneal dialysis catheter was removed. However, 8 months later he presented with symptoms of small bowel obstruction and gross blood stained ascites. He also underwent a laparotomy that confirmed the diagnosis of SEP after biopsy. The patient was started on 20 mg of tamoxifen twice a day. Both patients' symptoms were improved gradually with an increase of serum albumin and body weight. Tamoxifen may be useful in the treatment of patients diagnosed with SEP.
Collapse
Affiliation(s)
- P Moustafellos
- Oxford Transplant Unit, Oxford Radcliffe NHS Trust, Oxford, UK.
| | | | | | | | | | | | | |
Collapse
|
54
|
Chin AI, Yeun JY. Encapsulating Peritoneal Sclerosis: An Unpredictable and Devastating Complication of Peritoneal Dialysis. Am J Kidney Dis 2006; 47:697-712. [PMID: 16564950 DOI: 10.1053/j.ajkd.2005.12.049] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2005] [Accepted: 12/28/2005] [Indexed: 11/11/2022]
Affiliation(s)
- Andrew I Chin
- University of California Davis, Sacramento, CA 95817, USA
| | | |
Collapse
|
55
|
Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PEC, Augustine T, Riad H, Hutchison AJ, Taylor P, Pearson R, Gokal R. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2006; 68:2381-8. [PMID: 16221244 DOI: 10.1111/j.1523-1755.2005.00701.x] [Citation(s) in RCA: 121] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). It is characterized by a progressive, intra-abdominal, inflammatory process resulting in sheets of fibrous tissue that cover, bind, and constrict the viscera, thereby compromising the motility and function of the bowel. Although recent therapeutic approaches have been reported with variable success, the ability to detect reliably at an early stage patients at risk for EPS would be beneficial and allow treatment standardization. The aim of this study was to evaluate the clinical features of EPS and identify possible risk factors for its development in CAPD and APD patients. METHODS This was a review of all cases of EPS in a single center over the last 5 years. RESULTS There were 810 CAPD and APD patients, managed in our program over this period. We identified 27 cases of EPS, giving an overall of 3.3% in this population. The mean duration of CAPD before diagnosis of EPS was 72.6 +/- 39.7 months (range 16-172). Sixteen cases required surgical treatment and were classified as severe; others were treated conservatively (mild to moderate group). Ten patients received tamoxifen treatment with apparent benefit. The overall mortality rate was 29.6%. Eight patients from the severe group and the entire moderate group survived on hemodialysis or transplantation at 48.71 and 27.63 months follow-up, respectively. Peritonitis rates were not different between the 2 groups and peritoneal history was unremarkable compared to overall peritonitis rates in the unit. Data on small solute transport were not available in all patients in this retrospective analysis. CONCLUSION EPS is a serious, life-threatening complication of CAPD. Most cases had PD duration of more than 4 years. Careful monitoring by CT scans of the peritoneal membrane in patients beyond 5 years, and early catheter removal in patients with peritoneal thickening should be considered for long-term CAPD patients. Treatment with tamoxifen may be of benefit in these patients.
Collapse
Affiliation(s)
- Angela M Summers
- Department of Renal Medicine, Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
56
|
Courtney AE, Doherty CC. Fulminant sclerosing peritonitis immediately following acute bacterial peritonitis. Nephrol Dial Transplant 2005; 21:532-4. [PMID: 16293635 DOI: 10.1093/ndt/gfi275] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Sclerosing peritonitis (SP) is an uncommon disease in the peritoneal dialysis population, but the considerable morbidity and mortality associated with it make early diagnosis and treatment imperative. We describe a case illustrating that a fulminant variant of SP can occur as a second phase phenomenon immediately following treatment of acute bacterial peritonitis, a setting in which the diagnosis may be masked and aggressive immunosuppression considered potentially hazardous. Treatment with corticosteroid alone appears particularly effective for SP occurring in this setting.
Collapse
|
57
|
Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, Yamamoto H, Yokoyama K, Kawaguchi Y, Matsushima M. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005; 9:148-52. [PMID: 15980950 DOI: 10.1007/s10157-005-0349-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2004] [Accepted: 03/04/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND The present study was conducted to clarify the clinical risk factors related to the development of encapsulating peritoneal sclerosis (EPS), which is one of the most serious complications in patients undergoing peritoneal dialysis (PD). METHODS The records of 78 patients with a history of PD treatment, including 18 with EPS, were retrospectively analyzed (male/female, 51:27; age, 51.8 +/- 11.0 years; PD treatment, 94.1 +/- 42.7 months). The inclusion criteria were: duration of PD more than 24 months; 36-month follow up after discontinuation of PD; available data for dialysate-to-plasma creatinine ratio (D/P Cr), by fast peritoneal equilibration test within 3 months before PD discontinuation; and absence of EPS at PD discontinuation. Analytical parameters included age, sex, underlying renal disease, duration of PD, membrane transport state (higher transporter or lower transporter: D/P cr ratio more than or less than 0.75), number of episodes of peritonitis during PD treatment, performance of peritoneal lavage after PD discontinuation, and reasons for PD withdrawal (ultrafiltration failure, acute peritonitis, social matters). RESULTS Significant differences were noted regarding the PD duration, D/P cr, higher membrane transport state, and number of peritonitis episodes during PD. On receiver operating characteristic curves, the cutoff points for EPS were: D/P cr ratio, 0.74; number of peritonitis episodes, 2; and PD duration (months), 115.2. Multivariate analysis, employing the factors age, PD duration, higher membrane transport state, and number of peritonitis episodes, which were selected by stepwise analysis, identified the latter two factors as significant for the development of EPS (odds ratio [OR], 4.0; P = 0.046 and OR, 12.0; P = 0.049, respectively). CONCLUSIONS A higher transporter membrane state and the number of peritonitis episodes are factors contributing to the occurrence of EPS in patients who have experienced PD treatment.
Collapse
Affiliation(s)
- Ryo Yamamoto
- Department of Kidney and Hypertension, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo 105-8461, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
58
|
Di Paolo N, Sacchi G, Garosi G, Taganelli P, Gaggiotti E. Simple peritoneal sclerosis and sclerosing peritonitis: related or distinct entities? Int J Artif Organs 2005; 28:117-28. [PMID: 15770600 DOI: 10.1177/039139880502800207] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM The etiopathogenesis of sclerosing peritonitis is still debated, with some sustaining that it is a rare form of progression of simple peritoneal sclerosis and others that it is a primitive form. The aim of the present research was to clarify this question. MATERIAL AND METHODS 438 peritoneal biopsies from 253 patients were re-examined. 174 were obtained prior to peritoneal dialysis and 224 after various periods of dialysis. Forty biopsies were from peritoneal dialysis patients who developed sclerosing peritonitis. Peritoneal morphology was studied for signs of transition from simple sclerosis to sclerosing peritonitis. RESULTS Evidence was found sustaining the hypothesis that simple sclerosis to sclerosing peritonitis patients have distinct pathologies. CONCLUSIONS The results confirm previous observations, excluding the existence of any type of relation between simple peritoneal sclerosis to sclerosing peritonitis.
Collapse
Affiliation(s)
- N Di Paolo
- Department of Nephrology and Dialysis, University Hospital of Siena, 53100 Siena, Italy.
| | | | | | | | | |
Collapse
|
59
|
Kim BS, Choi HY, Ryu DR, Yoo TH, Park HC, Kang SW, Choi KH, Ha SK, Han DS, Lee HY. Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea. Yonsei Med J 2005; 46:104-11. [PMID: 15744812 PMCID: PMC2823035 DOI: 10.3349/ymj.2005.46.1.104] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Sclerosing encapsulating peritonitis (SEP) is a rare but serious complication in patients with continuous ambulatory peritoneal dialysis (CAPD), and is characterized by a progressive, intra-abdominal, inflammatory process resulting in the formation of sheets of new fibrous tissue, which cover, bind, and constrict the viscera, thereby compromising the motility of the bowel. No satisfactory estimate is available on the comparative incidence of dialysis related SEP and the pathogenesis of SEP still remains uncertain. Although recent therapeutic approaches have reported varying degrees of success, an efficient measure to detect, at an early stage, patients at risk for SEP would be beneficial and a standardized treatment regimen to prevent the illness is urgently needed. This study aimed to evaluate the clinical features of SEP and to identify the possible risk factors for the development of SEP in CAPD patients. We retrospectively reviewed by questionnaire SEP cases among CAPD patients from 7 university hospital dialysis centers in Korea, including Yonsei University, Ajou University, Catholic University, Inha University, Kyungpook University, Seoul National University and Soonchunhyang University, from January 1981 to December 2002. Out of a total of 4,290 CAPD patients in these centers, 34 cases developed SEP with an overall prevalence of 0.79%. The male to female ratio was 17:17. The median age of these patients was 44.5 years (range 19-66). The median duration of CAPD before SEP was 64 months (9-144) and 68% of patients (23/34) had been on CAPD for more than 4 years. Peritonitis (including two fungal cases) was the main cause of catheter removal in SEP (27 cases, 79%). Seventy-five percent of the cases (15/20) were administered beta-blocker for a mean duration of 85 months (26-130). Among 10 cases with available peritoneal equilibration test (PET) data, 8 showed high transporter characteristics, and the remaining 2 were high average. Eighteen cases were diagnosed by clinical and radiologic methods, and 16 were surgically diagnosed. Eleven cases were surgically treated and the others were treated conservatively with intermittent total parenteral nutrition (TPN). The overall mortality rate was 24%. SEP is a serious, life threatening complication of CAPD. Most cases had a PD duration of more than 4 years, a history of severe peritonitis, and high transporter characteristics in PET. Therefore, to reduce the incidence of SEP, careful monitoring and treatment, including early catheter removal in patients with severe peritonitis, should be considered for long-term CAPD patients with the above characteristics.
Collapse
Affiliation(s)
- Beom Seok Kim
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Hoon Young Choi
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Dong-Ryeol Ryu
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Tae Hyun Yoo
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Hyeong Cheon Park
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Shin Wook Kang
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Kyu Hun Choi
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Sung Kyu Ha
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Dae Suk Han
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| | - Ho Yung Lee
- Division of Nephrology, Department of Internal Medicine, College of Medicine, Institute of Kidney Disease, Yonsei University, Seoul, Korea
| |
Collapse
|
60
|
Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36. [PMID: 15086936 DOI: 10.1111/j.1523-1755.2004.00599.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Simple sclerosis consisted of a thin layer of submesothelial sclerotic tissue in peritoneal dialysis patients. Encapsulated peritoneal sclerosis (EPS) was characterized by thick sclerotic tissue involving vascular alterations in peritoneal dialysis patients. The objective of the present study is to evaluate serial morphologic changes and expressions of angiogenic factors [i.e., vascular endothelial growth factor (VEGF), angiopietin-1 (Ang-1), and angiopoietin-2 (Ang-2)] in EPS rat models. METHODS Twenty-four rats were given a daily intraperitoneal injection of chlorhexidine gluconate and ethanol dissolved in saline (CH). Nine rats were injected with CH and anti-VEGF neutralizing antibody simultaneously. Quantitative blood vessel evaluation was performed by staining for GS1-lectin. The mRNA expression of VEGF, Ang-1, Ang-2, and their receptors was evaluated by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical staining was performed in peritoneal vessels using anti-VEGF, Ang-1, and Ang-2 antibodies. Hematopoietic stem cells were detected using anti-CD34 antibody. RESULTS The vessel area, diameter, and length gradually increased until day 21, and then decreased. VEGF and Ang-2 mRNA expressions gradually increased until day 35. In contrast, Ang-1 peaked at day 21 and then decreased significantly. VEGF blockade improved the experimental EPS. In immunohistochemistry, the vessels stained by VEGF and Ang-2 were detected in subfibrous layer. CD34-positive cells were markedly stained at day 21. CONCLUSION Neoangiogenesis was observed in a rat model of experimental EPS. VEGF and angiopoietin/Tie system play an important role in the neoangiogenesis in this model. An analysis using this experimental rat model may elucidate the development of EPS in peritoneal dialysis patients.
Collapse
Affiliation(s)
- Hiroaki Io
- Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
61
|
Lee HY, Kim BS, Choi HY, Park HC, Kang SW, Choi KH, Ha SK, Han DS. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton) 2004; 8 Suppl:S33-9. [PMID: 15012689 DOI: 10.1046/j.1440-1797.8.s.11.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Sclerosing encapsulating peritonitis (SEP) is a rare yet serious complication in patients with continuous ambulatory peritoneal dialysis (CAPD). Incidence and prevalence of this syndrome have been defined in some large populations and a few single-centre experiences, but there is no satisfactory estimate of the comparative incidence of dialysis related SEP. The pathogenesis of SEP still remains uncertain, but there could be various causative factors. The diagnosis of SEP remains based on clinical suspicion confirmed with radiologic and/or pathologic findings. The possible variable etiologies and probable distinct pathways leading to this syndrome may make a uniform therapeutic approach unlikely. To determine the prevalence, etiologic factors, clinical features, effect of dialysis duration, and outcome of SEP in Korea, patients undergoing CAPD who developed SEP were retrospectively studied in five University Hospital dialysis centres with large numbers of CAPD patients in Korea. Out of a total 3888 CAPD studied patients between January 1981 to December 2002 in those five medical centres, 31 cases developed SEP with the overall prevalence 0.8%. There were 15 men and 16 women. The mean age of these patients was 44.0 +/- 9.8 years old. The mean duration of CAPD before SEP was 70.3 +/- 41.9 months (range 9-144 months) and 67.8% of patients (21/31) had been on CAPD more than 4 years. Peritonitis, including one fungal peritonitis, was the main cause of SEP in 25 cases (80.6%). Seventy percent of these cases used beta-blocker and the mean duration of the usage was 61.7 +/- 47.6 months. Seven cases were surgically treated and others were treated conservatively with intermittent total parenteral nutrition. The mortality rate was 25.8%. In conclusion, SEP is a serious life threatening complication of CAPD, and most cases had long-term peritoneal dialysis (PD) duration more than 4 years. To reduce the incidence of SEP, careful monitoring may be needed especially in patients with long-term CAPD and peritonitis.
Collapse
Affiliation(s)
- Ho Yung Lee
- Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
| | | | | | | | | | | | | | | |
Collapse
|
62
|
Outcome of Sclerosing Peritonitis Complicating Peritoneal Dialysis. Int J Organ Transplant Med 2004. [DOI: 10.1016/s1561-5413(09)60163-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
63
|
Abstract
A 65-year-old woman with end-stage renal disease (ESRD) presented with bloody ascites. She had been maintained on peritoneal dialysis (PD) for 7 years and had eight episodes of peritonitis. She was eventually transferred to hemodialysis (HD) because of ultrafiltration failure. This was associated with "high" peritoneal transport by peritoneal equilibration test (PET). A period of "peritoneal rest" did not improve PET results. Within a year of transfer to HD, ascites developed, which was hemorrhagic upon evaluation. A computed tomography (CT) scan suggested encapsulating sclerosing peritonitis, which was confirmed upon peritonoscopy. The patient was treated with prednisone and tamoxifen. Encapsulating peritoneal sclerosis (EPS) is a devastating complication of PD. Although it is rare and its development often unpredictable, this case demonstrates several clinical features commonly observed in the condition. These include more than 6 years on PD, a high transporter status, recurrent peritonitis, and the development of blood-stained dialysis effluent (or ascites if PD has been discontinued, as was the case in this patient). The initial presentation is often incipient with vague abdominal pain. Symptoms are progressive, however, and EPS has a high mortality rate, with most patients dying within 1 year of diagnosis, usually from malnutrition and sepsis. Treatment options include systemic immunosuppression and regular peritoneal irrigation after transfer to HD. Response to treatment is more likely to occur in the early inflammatory stage of EPS, when symptoms are nonspecific and imaging is relatively normal. Hence a high degree of suspicion for the diagnosis should be present in patients "at risk" of this condition, as early diagnosis is essential if progressive encapsulation of the abdominal viscera is to be prevented.
Collapse
Affiliation(s)
- Carol A Pollock
- Department of Medicine, Royal North Shore Hospital, Kolling Institute, University of Sydney, St. Leonards, Australia.
| |
Collapse
|
64
|
Gulati M, Meng MV, Freise CE, Stoller ML. Laparoscopic radical nephrectomy for suspected renal cell carcinoma in dialysis-dependent patients. Urology 2003; 62:430-6. [PMID: 12946741 DOI: 10.1016/s0090-4295(03)00467-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To characterize the treatment and outcomes of laparoscopic nephrectomy for suspected renal cancer in patients with dialysis-dependent renal failure. Laparoscopic nephrectomy is currently an accepted modality in the treatment of renal cell carcinoma in many patients. However, the indications for the minimally invasive approach in patients with renal dysfunction are unclear. End-stage renal disease has multiple manifestations associated with increased operative morbidity that are potentially amplified during laparoscopy. METHODS We reviewed our single-center experience for performing laparoscopic nephrectomy in patients with renal failure. Of patients receiving dialysis and having a kidney removed laparoscopically, 7 underwent the operation for suspected renal carcinoma because of a solid mass on imaging. The preoperative, intraoperative, and postoperative considerations were reviewed. RESULTS Of the 7 patients, 5 (71%) underwent successful removal of the kidney by laparoscopy. The amount of blood loss (120 mL) and the median time to discharge after surgery (3 days) were comparable to published data and our experience in patients with normal renal function; however, the operative time (mean 294 minutes) was longer. No recurrences had been detected at the last follow-up examination (median 21 months, range 18 to 51). Despite meticulous attention to perioperative and anesthetic considerations, two complications were observed-ileus and necrotizing fasciitis of the flank. CONCLUSIONS Pure laparoscopic nephrectomy for renal malignancy is feasible in patients with end-stage renal failure. However, this population is at increased risk of complications, despite maintaining the advantages of reduced blood loss and shorter hospitalization. The decision to proceed with laparoscopy and the selection of the specific surgical approach (transperitoneal or retroperitoneal) should be based on both surgeon experience and patient factors. In addition, careful preoperative preparation and intraoperative anesthetic management are crucial.
Collapse
Affiliation(s)
- Mittul Gulati
- Department ofUrology, University of California, San Francisco, School of Medicine, 94143-0738, USA
| | | | | | | |
Collapse
|
65
|
Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Ozono Y, Koji T, Kohno S. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003; 64:887-96. [PMID: 12911538 DOI: 10.1046/j.1523-1755.2003.00169.x] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Peritoneal fibrosis is a serious complication in patients on continuous ambulatory peritoneal dialysis (CAPD), but the molecular mechanism of this process remains unclear. Heat shock protein 47 (HSP47), a collagen-specific molecular chaperone, is essential for biosynthesis and secretion of collagen molecules, and is expressed in the tissue of human peritoneal fibrosis. In the present study, we examined the effect of HSP47 antisense oligonucleotides (ODNs) on the development of experimental peritoneal fibrosis induced by daily intraperitoneal injections of chlorhexidine gluconate (CG). METHODS HSP47 antisense or sense ODNs were injected simultaneously with CG from day 14, after injections of CG alone. Peritoneal tissue was dissected out 28 days after CG injection. The expression patterns of HSP47, type I and type III collagen, alpha-smooth muscle actin (alpha-SMA), as a marker of myofibroblasts, ED-1 (as a marker of macrophages), and factor VIII were examined by immunohistochemistry. RESULTS In rats treated with CG alone, the submesothelial collagenous compact zone was thickened, where the expression levels of HSP47, type I and type III collagen and alpha-SMA were increased. Marked macrophage infiltration was also noted and the number of vessels positively stained for factor VIII increased in the CG-treated group. Treatment with antisense ODNs, but not sense ODNs, abrogated CG-induced changes in the expression of HSP47, type I and III collagen, alpha-SMA, and the number of infiltrating macrophages and vessels. CONCLUSION Our results indicate the involvement of HSP47 in the progression of peritoneal fibrosis and that inhibition of HSP47 expression might merit further clinical investigation for the treatment of peritoneal fibrosis in CAPD patients.
Collapse
Affiliation(s)
- Tomoya Nishino
- Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
66
|
Affiliation(s)
- Maxwell V Meng
- Department of Urology, University of California, San Francisco, School of Medicine, 94143-0738, USA
| | | | | |
Collapse
|
67
|
Lopau K, Wanner C. Progressive anorexia and chronic ascites after termination of CAPD. Nephrol Dial Transplant 2002; 17:163-5. [PMID: 11773487 DOI: 10.1093/ndt/17.1.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Kai Lopau
- Department of Medicine, Division of Nephrology, University Hospital, Würzburg, Germany
| | | |
Collapse
|
68
|
Mehmet S, Quan G, Thomas S, Goldsmith D. Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis. Diabet Med 2001; 18:679-82. [PMID: 11553209 DOI: 10.1046/j.0742-3071.2001.00556.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIM Diabetes is now the commonest cause of end-stage renal failure, so there are many diabetic patients receiving dialysis therapy. There are several important ways in which dialysis practice can impinge unfavourably on glucose control. This study focuses on the interaction between maltose-derived metabolites in a new peritoneal dialysis fluid and blood glucose measurements using reagent sticks that depend on the glucose dehydrogenase method. CASE REPORT We report the cases of three patients, with insulin-treated diabetes and end-stage renal disease treated with peritoneal dialysis, who experienced symptomatic hypoglycaemia with inaccurate glucose readings on reagent strips when converted to icodextrin. CONCLUSION Careful teamwork between diabetes and renal physicians and specialist nurses is highly desirable to achieve good glucose control in a group of patients at particular risk of microvascular and macrovascular complications.
Collapse
Affiliation(s)
- S Mehmet
- Department of Diabetes, Endocrinology and Internal Medicine, Guy's Hospital, Guy's, King's and St. Thomas' Hospital Medical School, London, UK
| | | | | | | |
Collapse
|
69
|
Abstract
The frequency, pathology, animal models, pathogenesis, clinical manifestations, diagnostic criteria, therapy and prevention of peritoneal sclerosis are reviewed. Many of these aspects have a bimodal configuration which suggests that peritoneal sclerosis, usually considered a single pathology in peritoneal dialysis, is actually two distinct nosological entities: simple sclerosis and sclerosing peritonitis. The former is very frequent, with minor anatomical alterations and low clinical impact; it is reproducible in animals by means of peritoneal dialysis, and is clearly due to the poor biocompatibility of peritoneal dialysis solutions. The latter is rare, with radical anatomical alterations and high mortality requiring valid methods of diagnosis, therapy and prevention; it can only be reproduced in animal models by means other than peritoneal dialysis and seems to be due to factors both related and unrelated to peritoneal dialysis.
Collapse
Affiliation(s)
- G Garosi
- Nephrology and Dialysis Department, Le Scotte Hospital, Siena, Italy.
| | | |
Collapse
|
70
|
Shioshita K, Miyazaki M, Ozono Y, Abe K, Taura K, Harada T, Koji T, Taguchi T, Kohno S. Expression of heat shock proteins 47 and 70 in the peritoneum of patients on continuous ambulatory peritoneal dialysis. Kidney Int 2000; 57:619-31. [PMID: 10652040 DOI: 10.1046/j.1523-1755.2000.00883.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Peritoneal sclerosis, characterized by collagen accumulation, is a serious complication in continuous ambulatory peritoneal dialysis (CAPD) therapy. Heat shock protein 47 (HSP47) is a collagen-specific molecular chaperon and is closely associated with collagen synthesis. METHODS We determined the expression of HSP47 and HSP70 (nonspecific for collagen synthesis) by immunohistochemistry in peritoneal tissues of patients on CAPD. The tissue for collagen III, alpha-smooth muscle actin (alpha-SMA), and CD68 (a marker for macrophages) were also stained. Thirty-two peritoneal samples were divided into three groups (group A1, 11 patients who had no ultrafiltration loss; group A2, 9 patients who had ultrafiltration loss; and group B, 12 specimens who had end-stage renal disease prior to induction of CAPD. RESULTS In group B, staining for HSP47, HSP70, and collagen III in peritoneal tissues was faint, and only a few cells were positive for alpha-SMA and CD68. In contrast, HSP47, HSP70, and collagen III were expressed in areas of thickened connective tissues in fibrotic peritoneal specimens of CAPD patients. The expression level of HSP47, HSP70, collagen III, and alpha-SMA and the number of CD68-positive cells in group A2 were significantly higher than those in groups A1 and B. HSP47/HSP70-positive cells were mesothelial cells, adipocytes, and alpha-SMA-positive myofibroblasts. Furthermore, the expression level of HSP47 was significantly higher in peritoneal specimens from patients with refractory peritonitis than without it and was significantly higher in patients with more than 60 months of CAPD therapy than that in patients with less than 60 months of CAPD. CONCLUSION Our results indicate that CAPD therapy may induce HSPs in the peritoneal tissue, and that peritonitis in CAPD patients may be associated with the progression of peritoneal sclerosis at least through HSP47 expression and chronic macrophage infiltration. Our data also suggest that the progression of peritoneal sclerosis in such patients is associated with deterioration of peritoneal ultrafiltration function.
Collapse
Affiliation(s)
- K Shioshita
- The Second Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|